Brief: Burning Rock Biotech Receives Breakthrough Device Designation From China's NMPA
16/10/2023 07:19
Oct 16 (Reuters) - Burning Rock Biotech Ltd BNR.O :
* RECEIVED BREAKTHROUGH DEVICE DESIGNATION FROM CHINA'S NMPA
FOR
ITS MULTI-CANCER EARLY DETECTION TEST
Source text for Eikon: ID:nRSP1973Qa
Further company coverage: BNR.O
((Reuters.Briefs@thomsonreuters.com;;))
Recent news on Burning Rock Biotech
See all newsBurning Rock Biotech's Q2 revenue falls, net loss widens on central laboratory weakness
China's Burning Rock Biotech Q1 revenue falls on lower test volumes
China's Burning Rock Biotech Q4 net loss narrows as costs fall
Cancer diagnostics firm Burning Rock Biotech's Q3 revenue rises on pharma R&D growth
Brief: Burning Rock's Oncoguide™ Oncoscreen™ Plus CDX System Now Approved In Japan As A Companion Diagnostic For Capivasertib In Breast Cancer